Search Results | Blood | American Society of Hematology

1-20 of 429

2 3 4 5

Sort by

Sort Order Select

Journal Articles

Prognostic value of interim FDG-PET in diffuse large cell lymphoma: results from the CALGB 50303 Clinical Trial

Heiko Schöder, Mei-Yin C. Polley, Michael V. Knopp, Nathan Hall, Lale Kostakoglu, Jun Zhang, Howard R. Higley, Gary Kelloff, Heshan Liu, Andrew D. Zelenetz, Bruce D. Cheson, Nina Wagner-Johnston, Brad S. Kahl, Jonathan W. Friedberg, Eric D. Hsi, John P. Leonard, Lawrence H. Schwartz, Wyndham H. Wilson, Nancy L. Bartlett

Blood (2020) 135 (25): 2224–2234.

DOI: https://doi.org/10.1182/blood.2019003277

Published: 2020

Includes: Supplemental data

Journal Articles

Hotter is not more aggressive: baseline SUVmax in FL

N. George Mikhaeel

Blood (2020) 135 (15): 1191–1192.

DOI: https://doi.org/10.1182/blood.2020004986

Published: 2020

Journal Articles

Prognostic Value of Total Metabolic Tumor Volume and Total Lesion Glycolysis Measured By 18F-FDG PET-CT in Patients with T-Cell Lymphoblastic Lymphoma

Xiaoyan Feng, Xin Wen, Ling Li, Xin Li, Sun Zhenchang, Lei Zhang, Lugui Qiu, MD PhD, Mingzhi Zhang, MD PhD

Blood (2019) 134 (Supplement_1): 2851.

DOI: https://doi.org/10.1182/blood-2019-130091

Published: 2019

Journal Articles

Krd Consolidation in Myeloma Patients with a Positive PET-CT after Standard First Line Treatment: A Phase II Study (CONPET)

Jakob Nordberg Nørgaard, MD, Niels Abildgaard, MD, Anna Lysén, MSc, Mona-Elisabeth R Revheim, MD PhD, James P Connelly, MD PhD, Fredrik H. Schjesvold, MD PhD

Blood (2019) 134 (Supplement_1): 3172.

DOI: https://doi.org/10.1182/blood-2019-125523

Published: 2019

Journal Articles

Clinical Impact of 18 f-FDG PET/CT As a Valuable Prognostic Tool for the Newly Diagnosed Multiple Myeloma with Extramedullary Disease

Dong Won Baek, MD, Hee Jeong Cho, Sang Kyun Sohn, MD PhD, Sung-Hoon Jung, MD, Hong chae Moon, Joon Ho Moon, MD

Blood (2019) 134 (Supplement_1): 3142.

DOI: https://doi.org/10.1182/blood-2019-129831

Published: 2019

Journal Articles

Prognostic Significance of Interim PET/CT Assessment for the Treatment of Advanced Stage of Marginal Zone Lymphoma in the Post Immunochemotherapy Era

Ga-Young Song, Seok Jin Kim, MD PhD, Sang Eun Yoon, Jin Seok Kim, MD PhD, Ho-Young Yhim, MD PhD, Youngil Koh, MD PhD, Sung Yong Oh, MD PhD, Ho Sup Lee, MD PhD, Ho-Jin Shin, MD PhD, Young Rok Do, MD PhD, Won Sik Lee, MD PhD, Lee Gyeong-Won, Dae Sik Kim, Yong Park, Deok-Hwan Yang, MD PhD

Blood (2019) 134 (Supplement_1): 4002.

DOI: https://doi.org/10.1182/blood-2019-126574

Published: 2019

Journal Articles

Baseline Metabolic Tumor Volume in 18FDG-PET-CT Scans in Classical Hodgkin Lymphoma Using Semi-Automatic Segmentation

Julia Driessen, BSc, Gerben J.C. Zwezerijnen, MD, Jakoba J Eertink, MSc, Marie José Kersten, MD PhD, Anton Hagenbeek, MD PhD, Otto S Hoekstra, MD PhD, Josée M Zijlstra, MD PhD, Ronald Boellaard, MSc, PhD

Blood (2019) 134 (Supplement_1): 4049.

DOI: https://doi.org/10.1182/blood-2019-125495

Published: 2019

Journal Articles

Response-Adapted Therapy in HIV-Associated Diffuse Large B-Cell Lymphoma: Updated Results of a Prospective Phase II Study of Short-Course-EPOCH-RR

Jaime P. Gastwirt, MD, Mark A. Ahlman, MD, Christopher Melani, MD, Stefania Pittaluga, MD PhD, Kieron Dunleavy, MD, Andrea Nicole Lucas, RN, Seth M. Steinberg, PhD, Elaine S. Jaffe, MD, Wyndham Wilson, MD, Mark Roschewski, MD

Blood (2019) 134 (Supplement_1): 4080.

DOI: https://doi.org/10.1182/blood-2019-122450

Published: 2019

Journal Articles

The IMiD-Target Cereblon Determines Transmembrane Protein Quality Control Promoting Tumor Metabolism

Michael Heider, Ruth Eichner, Jacob Stroh, Anna Kuisl, Jana Zecha, Jannis Lawatscheck, Martina Rudelius, Anne-Kathrin Garz, Simone Lemeer, Christian Peschel, Ulrich Keller, MD, Katharina Götze, Johannes Buchner, Bernhard Kuster, Vanesa Fernandez-Saiz, Florian Bassermann, MD PhD

Blood (2019) 134 (Supplement_1): 314.

DOI: https://doi.org/10.1182/blood-2019-129064

Published: 2019

Journal Articles

PET-Directed Therapy for Patients with Limited-Stage Diffuse Large B-Cell Lymphoma - Results of Intergroup Nctn Study S1001

Daniel O. Persky, MD, Hongli Li, MS, Deborah M. Stephens, DO, Steven I Park, MD, Nancy L. Bartlett, MD, Lode J. Swinnen, MB ChB, Paul M. Barr, MD, Jerome D. Winegarden, III, MD, Louis S. Constine, MD, Thomas J. Fitzgerald, MD, John P. Leonard, MD, Brad S. Kahl, MD, Michael L. Leblanc, PhD, Joo Y. Song, MD, Richard I. Fisher, MD, Lisa M. Rimsza, MD, Sonali M. Smith, MD, Jonathan W. Friedberg, MD

Blood (2019) 134 (Supplement_1): 349.

DOI: https://doi.org/10.1182/blood-2019-123871

Published: 2019

Journal Articles

High Metabolic Heterogeneity on Baseline 18F-FDG PET/CT Predicts Worse Prognosis of Newly Diagnosed Diffuse Large B-Cell Lymphoma

Hajime Senjo, MD, Kenji Hirata, MD PhD, Koh Izumiyama, MD PhD, Koichiro Minauchi, MD, Kazuo Itoh, Eriko Tsukamoto, Akio Mori, Shuichi Ota, Daigo Hashimoto, Takanori Teshima, MD

Blood (2019) 134 (Supplement_1): 488.

DOI: https://doi.org/10.1182/blood-2019-124390

Published: 2019

Journal Articles

Complete Response Status According to RECIL 2017 Criteria Shows High Concordance with Lugano 2014 Criteria and Is Highly Prognostic for Outcome in Previously Untreated Patients with CD20-Positive Diffuse Large B-Cell Lymphoma (DLBCL)

Lale Kostakoglu, MD MPH, Maurizio Martelli, MD, Laurie H Sehn, MD, Marek Trněný, MD, Umberto Vitolo, Andrea Knapp, PhD, Federico Mattiello, PhD, Tina G Nielsen, MD PhD, Deniz Sahin, BSc, Gila Sellam, PhD, Carol Ward, MSc, Anas Younes, MD

Blood (2019) 134 (Supplement_1): 489.

DOI: https://doi.org/10.1182/blood-2019-123626

Published: 2019

Journal Articles

The Optimal Timing of Interim 18F-FDG PET in Diffuse Large B-Cell Lymphoma: An Individual Patient Data Meta-Analysis By the Petra Consortium

Blood (2019) 134 (Supplement_1): 487.

DOI: https://doi.org/10.1182/blood-2019-122298

Published: 2019

Journal Articles

Clinical Significance of Uptake Value on F18-FDG PET/CT and Histological Grade in 164 Patients with Follicular Lymphoma Including Transformation - a Single Center Retrospective Study

Mitsuhiro Yuasa, MD, Daisuke Kaji, MD, Kosei Kageyama, MD, Yuki Taya, MD PhD, Shinsuke Takagi, Hisashi Yamamoto, MD PhD, Yuki Asano-Mori, MD PhD, Akiko Yoneyama, MD PhD, Shigeyoshi Makino, MD PhD, Naoyuki Uchida, MD PhD, Shuichi Taniguchi, MD PhD, Go Yamamoto, MD PhD

Blood (2019) 134 (Supplement_1): 1529.

DOI: https://doi.org/10.1182/blood-2019-130837

Published: 2019

Journal Articles

A Phase 1 a/b Dose Escalation Trial to Evaluate the Safety and Tolerability of CG-806 in Patients with Relapsed or Refractory CLL/SLL or Non-Hodgkin's Lymphomas

Stephen B Howell, MD, Hongying Zhang, MD PhD, William G Rice, PhD

Blood (2019) 134 (Supplement_1): 5477.

DOI: https://doi.org/10.1182/blood-2019-130784

Published: 2019

Journal Articles

A Pilot Trial of Adriamycin, Pembrolizumab, Vinblastine and Dacarbazine (APVD) for Patients with Untreated Classical Hodgkin Lymphoma

Ryan C. Lynch, MD, Chaitra S. Ujjani, MD, Edus H. Warren, MD PhD, David M. Kurtz, MD PhD, Hilary Coye, PA-C, Jacquelin Vandermeer, BS, Hongyan Du, MD, Adam Greenbaum, MD PhD, Ajay K. Gopal, MD

Blood (2019) 134 (Supplement_1): 5299.

DOI: https://doi.org/10.1182/blood-2019-124997

Published: 2019

Journal Articles

End-of-Treatment 18[F]-FDG PET Can Predict Progression-Free Survival in Patients Undergoing Bendamustine + Rituximab for First Relapsed/Recurrent Follicular Lymphoma: The Result of W- J H S NHL01 Study

Shinya Rai, MD PhD, Koji Kato, MD PhD, Junji Suzumiya, MD PhD, Koji Izutsu, MD PhD, Momoko Nishikori, MD PhD, Hirohiko Shibayama, MD PhD, Yoshinobu Maeda, MD PhD, Kenichi Yoshimura, PhD, Ukihide Tateishi, MD PhD, Toshihiro Miyamoto, MD PhD, Jun Ishikawa, MD PhD, Tsutomu Takahashi, MD PhD, Takahiro Yamauchi, MD PhD, Koichi Akashi, MD PhD, Yuzuru Kanakura, MD PhD

Blood (2019) 134 (Supplement_1): 5245.

DOI: https://doi.org/10.1182/blood-2019-126455

Published: 2019

Journal Articles

Gastrointestinal (GI) Involvement with Non-Hodgkin's Lymphoma (NHL) Impacts Outcome; A Retrospective Single Tertiary Care Center Analysis of Clinico-Pathologic Characteristics Provides an Alternate Insight to Presentation and Outcome

Ghada Zakout, FRCPATH, MRCP (UK), MBBCh (Hon), Charalampia Kyriakou

Blood (2019) 134 (Supplement_1): 5246.

DOI: https://doi.org/10.1182/blood-2019-127152

Published: 2019

Journal Articles

Impact of the Association between Tgl and EZH2 Mutations (Y641N/Y641F/Y641H/Y641S) on Disease Free Survival of Patients with Diffuse Large B-Cell Lymphoma

Myrna Candelaria, MD PharmD, Adriana Palacios Campos, MD, Olga Gutierrez Hernandez, QFB, Alejandro Aviles, MD, Uvi Cancino-Ramos, MD, Lucia Taja Chayeb, PhD, Osvaldo García-Perez, MD, David Cantú de León

Blood (2019) 134 (Supplement_1): 5222.

DOI: https://doi.org/10.1182/blood-2019-125906

Published: 2019

Journal Articles

Comparison of CT and PET-Based Assessments per Lugano Criteria in FDG-Avid Lymphoma- a Retrospective Analysis of Independent Review Assessments

Jayant Narang, MD, Surabhi Bajpai, MD, Rudresh Rajnikant Jarecha, MBBS, MD, Sayali Karve, PhD, Katarina Ludajic, PhD, Manish Sharma, MD, Shweta Narang, MD, Michael O'Connor, PhD

Blood (2019) 134 (Supplement_1): 5277.

DOI: https://doi.org/10.1182/blood-2019-130570

Published: 2019

2 3 4 5

NARROW

Prognostic value of interim FDG-PET in diffuse large cell lymphoma: results from the CALGB 50303 Clinical Trial

Hotter is not more aggressive: baseline SUVmax in FL

Prognostic Value of Total Metabolic Tumor Volume and Total Lesion Glycolysis Measured By 18F-FDG PET-CT in Patients with T-Cell Lymphoblastic Lymphoma

Krd Consolidation in Myeloma Patients with a Positive PET-CT after Standard First Line Treatment: A Phase II Study (CONPET)

Clinical Impact of 18 f-FDG PET/CT As a Valuable Prognostic Tool for the Newly Diagnosed Multiple Myeloma with Extramedullary Disease

Prognostic Significance of Interim PET/CT Assessment for the Treatment of Advanced Stage of Marginal Zone Lymphoma in the Post Immunochemotherapy Era

Baseline Metabolic Tumor Volume in 18FDG-PET-CT Scans in Classical Hodgkin Lymphoma Using Semi-Automatic Segmentation

Response-Adapted Therapy in HIV-Associated Diffuse Large B-Cell Lymphoma: Updated Results of a Prospective Phase II Study of Short-Course-EPOCH-RR

The IMiD-Target Cereblon Determines Transmembrane Protein Quality Control Promoting Tumor Metabolism

PET-Directed Therapy for Patients with Limited-Stage Diffuse Large B-Cell Lymphoma - Results of Intergroup Nctn Study S1001

High Metabolic Heterogeneity on Baseline 18F-FDG PET/CT Predicts Worse Prognosis of Newly Diagnosed Diffuse Large B-Cell Lymphoma

Complete Response Status According to RECIL 2017 Criteria Shows High Concordance with Lugano 2014 Criteria and Is Highly Prognostic for Outcome in Previously Untreated Patients with CD20-Positive Diffuse Large B-Cell Lymphoma (DLBCL)

The Optimal Timing of Interim 18F-FDG PET in Diffuse Large B-Cell Lymphoma: An Individual Patient Data Meta-Analysis By the Petra Consortium

Clinical Significance of Uptake Value on F18-FDG PET/CT and Histological Grade in 164 Patients with Follicular Lymphoma Including Transformation - a Single Center Retrospective Study

A Phase 1 a/b Dose Escalation Trial to Evaluate the Safety and Tolerability of CG-806 in Patients with Relapsed or Refractory CLL/SLL or Non-Hodgkin's Lymphomas

A Pilot Trial of Adriamycin, Pembrolizumab, Vinblastine and Dacarbazine (APVD) for Patients with Untreated Classical Hodgkin Lymphoma

End-of-Treatment 18[F]-FDG PET Can Predict Progression-Free Survival in Patients Undergoing Bendamustine + Rituximab for First Relapsed/Recurrent Follicular Lymphoma: The Result of W- J H S NHL01 Study

Gastrointestinal (GI) Involvement with Non-Hodgkin's Lymphoma (NHL) Impacts Outcome; A Retrospective Single Tertiary Care Center Analysis of Clinico-Pathologic Characteristics Provides an Alternate Insight to Presentation and Outcome

Impact of the Association between Tgl and EZH2 Mutations (Y641N/Y641F/Y641H/Y641S) on Disease Free Survival of Patients with Diffuse Large B-Cell Lymphoma

Comparison of CT and PET-Based Assessments per Lugano Criteria in FDG-Avid Lymphoma- a Retrospective Analysis of Independent Review Assessments

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only